
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow Inc. has positioned itself advantageously in the biopharmaceutical landscape, particularly as the market for biosimilars expands, capturing over 40% market share in key therapeutic categories. The company's flagship product, VEVYE, has demonstrated strong performance with a 22% quarter-over-quarter revenue growth, reaching $22.6 million in the third quarter of 2025, and achieving a 10.5% share of the national dry eye disease market. Looking ahead, there is strong confidence in the company’s potential to exceed a quarterly revenue run rate of $250 million by the fourth quarter of 2027, which would represent a fourfold increase compared to the actuals reported in the second quarter of 2025, thus signaling robust prospects for long-term revenue and margin expansion.
Bears say
The financial outlook for Harrow Inc is negatively impacted by several fundamental risks, including the potential for its pipeline products to fail in clinical trials or receive regulatory approval, which could significantly diminish their market opportunity and valuation. Additionally, the company faces challenges such as lower-than-projected product uptake, the burden of existing debt, and the necessity to raise capital, which may lead to shareholder dilution. Furthermore, the potential introduction of unfavorable regulations could adversely affect the company's operations and financial performance.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares